Skip to Content
Merck
CN
  • Engineering cytochrome P450 monooxygenase CYP 116B3 for high dealkylation activity.

Engineering cytochrome P450 monooxygenase CYP 116B3 for high dealkylation activity.

Biotechnology letters (2010-03-10)
Luo Liu, Rolf D Schmid, Vlada B Urlacher
ABSTRACT

Cytochrome P450 monooxygenase CYP116B3 from Rhodococcus ruber catalyzes the dealkylation of 7-ethoxycoumarin and the hydroxylation of substituted and unsubstituted aromatics. However, since activities were quite low, a combination of site-specific mutagenesis and directed evolution was applied to produce 7800 variants of CYP116B3, which were screened via a newly developed high-throughput screening system based on the dealkylation of 7-ethoxycoumarin catalyzed by recombinant E. coli. The best mutant was found after four rounds of directed evolution and had a 240-fold increased deethylation activity toward 7-ethoxycoumarin (223 nmol product/nmol P450.min) and a 10-fold increased demethylation activity toward 7-methoxycoumarin (9 nmol product/nmol P450.min).

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
7-Ethoxycoumarin